Welcome to our dedicated page for Rapid Micro Biosystems news (Ticker: RPID), a resource for investors and traders seeking the latest updates and insights on Rapid Micro Biosystems stock.
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) is a life sciences technology company that regularly issues news and updates related to its automated microbial quality control (MQC) solutions for pharmaceutical and biopharmaceutical manufacturing. Company press releases focus on the performance and adoption of its flagship Growth Direct system, which automates and modernizes manual MQC testing workflows used in large and complex pharmaceutical manufacturing operations across the globe.
News for RPID often covers quarterly and annual financial results, including product revenue, service revenue, and recurring revenue from consumables and annual service contracts. The company highlights metrics such as system placements, customer system validations, recurring revenue growth, and record consumable revenue. Updates have also described record multi-system orders from an existing Top 20 global biopharma customer to automate a global manufacturing network across North America, Europe, and Asia Pacific.
Investors and industry followers can also expect announcements about capital structure and financing, such as the disclosed five-year, $45 million term loan facility with Trinity Capital Inc., as well as news on the company’s financial position and outlook. Additional news items include participation in major healthcare and investor conferences, including the J.P. Morgan Healthcare Conference, the Stifel Healthcare Conference, and the H.C. Wainwright Global Investment Conference, where management presents and engages with analysts and investors.
This RPID news page on Stock Titan aggregates these types of updates so readers can quickly review earnings announcements, financing developments, system placement milestones, and conference participation related to Rapid Micro Biosystems. Users interested in the evolution of automated microbial quality control in biopharma manufacturing can monitor this feed for the company’s latest publicly released information.
Rapid Micro Biosystems (Nasdaq: RPID) will announce its fourth quarter and full year 2021 financial results on March 4, 2022, before the market opens. The management team will host a webcast conference call at 8:30 a.m. EST on the same day, accessible via their website. Rapid Micro specializes in automated solutions for microbial quality control in pharmaceutical manufacturing, ensuring faster and safer healthcare product releases. Their flagship product, the Growth Direct System, modernizes traditional testing methods, enhancing efficiency and regulatory compliance.
Rapid Micro Biosystems (Nasdaq: RPID) announced the appointment of Michael Beaulieu as Vice President of Investor Relations and Corporate Communications. Beaulieu, with over 20 years in the industry, most recently served at Integra LifeSciences, where he earned recognition as a top IR professional. His expertise is expected to enhance RPID's outreach and investor engagement, ultimately aiming to create long-term shareholder value. The company specializes in automation solutions for healthcare product manufacturing, including biologics and vaccines, driving significant operational benefits.
Rapid Micro Biosystems (Nasdaq: RPID) has announced its preliminary unaudited revenue for Q4 2021, estimating total revenue between $4.7 million and $5.2 million, with commercial revenue between $4.5 million and $4.9 million. For the full year 2021, total revenue is expected at $22.8 to $23.3 million. Looking ahead, the company projects 2022 commercial revenue of $27 million to $32 million, representing growth of 25% to 50%. Despite challenges from COVID-19, Rapid Micro secured growth in recurring revenue, expecting a 90% increase in the last quarter of 2021.
Rapid Micro Biosystems (Nasdaq: RPID) announced the appointment of Inese Lowenstein to its Board of Directors, bringing extensive leadership experience from companies like Danaher and Merck. CEO Robert Spignesi expressed enthusiasm, noting Lowenstein's track record in customer-focused innovation and strategic growth. Her expertise in life sciences is expected to enhance the company’s mission to be a leader in microbial quality control. Lowenstein has over 20 years of experience in various leadership roles, reinforcing Rapid Micro's commitment to innovative healthcare solutions.
Rapid Micro Biosystems reported third quarter 2021 revenues of $6.9 million, with commercial revenue at $6.3 million, a 27% increase year-over-year. The company reaffirmed its full-year commercial revenue outlook of at least $24.0 million, indicating 70% growth over 2020. Recurring commercial revenue surged by 154% to $2.2 million. Despite these positive trends, net loss widened to ($25.0 million) from ($8.5 million) in Q3 2020, largely due to increased operating costs and charges related to the IPO. Cash on hand stood at $220 million.
Rapid Micro Biosystems (Nasdaq: RPID) will participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021. CEO Rob Spignesi and CFO Sean Wirtjes will lead a 30-minute Q&A session at 6:20 am PT/9:20 am ET. A live webcast will be available on the company's website and archived for 90 days. Rapid Micro specializes in automation solutions for healthcare manufacturing, enhancing the efficiency of microbial quality control testing. Its flagship Growth Direct® System modernizes testing workflows in pharmaceutical manufacturing, ensuring safe product releases.
Rapid Micro Biosystems (Nasdaq: RPID) will release its third quarter 2021 financial results on November 11, 2021, after market close. A conference call is scheduled for November 12, 2021, at 5:00 AM PT, where company management will discuss the results. The call will be accessible via live webcast on their website and archived for 90 days. Rapid Micro provides automation solutions to enhance the production and release of healthcare products, including biologics and vaccines, while ensuring compliance with quality control regulations.
Rapid Micro Biosystems, Inc. (Nasdaq: RPID) has appointed Andy Keys as Chief Commercial Officer, effective October 1, 2021. Keys, a veteran with over twenty years in the life sciences sector, previously served at Quanterix Corporation. His expertise will enhance Rapid Micro's global sales, service, and validation teams. Key highlights include the company's flagship Growth Direct® System, which automates microbial quality control in pharmaceutical manufacturing, promising faster results and improved efficiency in healthcare product releases.
Rapid Micro Biosystems (Nasdaq: RPID) announced its participation in the 2021 Parenteral Drug Association Pharmaceutical Microbiology Conference from October 4-6. The company will showcase its Growth Direct® System, which enhances microbial quality control in pharmaceutical manufacturing. Key achievements include a successful IPO, regulatory approvals in Europe and the U.S., and the sale of its one millionth consumable. Attendees can preview a new rapid sterility test and access informative resources on quality control.
Rapid Micro Biosystems (Nasdaq: RPID) announced its inclusion in the Russell 2000®, Russell 3000®, and Russell Microcap® indexes, effective September 20, 2021. This membership is based on market-capitalization rankings and style attributes, remaining effective for a year. CEO Rob Spignesi noted that this inclusion will enhance stock visibility in the investment community, aiding the company’s mission to improve microbial quality control in pharmaceutical manufacturing. The company specializes in automation solutions for healthcare product manufacturing, with a focus on safety and efficiency.